Gilead's quarterly loss is narrower than expected
By Ciara Linnane
Drug company's stock dips in after-hour trading
Gilead Sciences Inc.'s stock dipped 0.2% in after-hours trading Thursday, after the drug company's adjusted first-quarter profit was narrower than expected.
Gilead (GILD) posted a net loss of 4.17 billion, or $3.34 a share, for the quarter, after reporting income of $1.01 billion, or 80 cents a share, in the year-earlier period.
Excluding one-time items, the company's per-share loss came to $1.32, narrower than the $1.49 loss expected by FactSet analysts. The loss was mostly due to the $4.1 billion of acquired IPR&D expenses associated with the $3.9 billion acquisition of CymbaBay, which closed on March 22.
Revenue rose to $6.686 billion from $6.352 billion a year ago, ahead of the $6.357 billion FactSet consensus.
Chief Executive Daniel O'Day said revenue was driven by HIV, oncology and liver-disease products.
"The acquisition of CymaBay brings us another potentially transformative therapy for people with liver disease, and a regulatory decision on seladelpar is expected in August" he said in prepared remarks.
"New HIV data demonstrates the continued progress in our long-acting HIV pipeline, and we look forward to providing updates on this and our broad Oncology portfolio throughout the rest of 2024," O'Day said.
The company is still expecting full-year revenue of $27.1 billion to $27.5 billion.
It lowered its full-year adjusted per-share earnings guidance to $3.45 to $3.85, from earlier guidance of $6.85 to $7.25.
The stock has fallen 19% in the year to date, while the S&P 500 SPX has gained 6%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
04-25-24 2021ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks